Perspectives

October 2026

1. Oct 30
   U.S. sets ten conditions for pharmacies to compound six unapproved peptides, with 14 days to comment

   The HHS peptide enforcement-discretion notice printed in the Federal Register on October 30, 2026, opening a comment period that closes November 13. The policy document behind it sets ten conditions, and the ones about documentation of the bulk substance are a specification the research market will now be compared against. What printed, what the conditions are, what was said this week, and what to watch.

2. Oct 29
   Coroner finds prescribed, compounded peptides caused Australia's first confirmed peptide death, of stunt coordinator Richard Norton

   The Victorian coroner found that Richard Norton died of complications from prescribed, pharmacy-compounded peptides CJC-1295 and ipamorelin, used in more than the amount prescribed. What the findings say, what FDA said about the same two molecules in 2023, why a prescription and a consent form changed nothing about them, and why the United States is building the same pipeline anyway.

3. Oct 28
   U.S. health secretary overrules FDA to let pharmacies compound BPC-157 and five other unapproved peptides

   On October 28, 2026 HHS filed a notice saying it will not enforce against pharmacies compounding six peptides, BPC-157, KPV, TB-500, MOTS-c, epitalon and semax, over the written objections of FDA's reviewers. What was filed, how it got here, what it does and does not change, and why it sharpens rather than moves the line for research-labeled products.

4. Oct 27
   Our products are not designed for humans. Our brand is.

   How to recognize a research-peptide site that was generated rather than built, why that matters before you trust its certificates, and how this shop was made: product pages, stylesheet, labels and brand by hand, numbers computed and tested, AI used openly under people who can tell when it is wrong.

5. Oct 27
   The cheapest research-peptide sellers are the ones that vanish, and their certificates of analysis vanish with them

   What a lost peptide supplier costs a research program, the visible profile of the suppliers that disappear, what the warning letters and the 2026 lawsuits were actually aimed at, and a five-minute check for any supplier.

6. Oct 26
   Eli Lilly has sued 11 sellers of retatrutide, its unapproved experimental peptide, and no court has ruled yet

   Eleven suits over one peptide in eleven weeks, and no ruling yet. What Lilly pleaded and left out, what has happened on each docket, where the theory is strong and where it is open, and what the cases will turn on.

7. Oct 22
   FDA decides whether a research peptide is an illegal drug from what its seller says, and no court reviews the call

   A research peptide's intended use is decided by inference, from any relevant source, by the agency that also publishes the conclusion, in letters no court will review. How that works, and the questions it leaves open.